

SHARE BUYBACK PROGRAM NOVOZYMES A/S B SHARES

September 7, 2012

On January 20, 2012, Novozymes initiated a share buyback program in accordance with the provisions of European Commission Regulation no. 2273/2003 of December 22, 2003, also referred to as the Safe Harbour Regulation.

Under the program Novozymes will buy back B shares for an amount of up to DKK 1,000 million in the period from January 20, 2012, to December 31, 2012.

The following transactions have been made under the program:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	4,209,372		663,280,273
August 31, 2012	24,585	164.16	4,035,896
September 3, 2012	20,000	167.20	3,343,962
September 4, 2012	28,000	166.84	4,671,607
September 5, 2012	22,112	165.71	3,664,198
September 6, 2012	15,000	168.51	2,527,664
Accumulated under the program	4,319,069		681,523,600

Transactions related to Novozymes' incentive programs have resulted in a net sale by Novozymes of 20,805 B shares in the period from August 31, to September 6, 2012. The shares related to these transactions were not part of the Safe Harbour share buyback program.

With the transactions stated above, Novozymes owns a total of 12,040,136 treasury shares, corresponding to 3.7% of the share capital. The total amount of shares in the company is 325,000,000 including treasury shares.

Contact persons:

Press and media:

René Tronborg (Europe)

Tel. (direct): +45 4446 2274

Tel. (mobile): +45 3077 2274

Paige Donnelly (USA)

Tel. (direct): +1 919 494 3209

Tel. (mobile): +1 919 218 4501

Investor relations:

Maarit Pokkinen

Tlf. (direkte): +45 4446 8682

Tlf. (mobil): +45 3077 8682

Martin Riise

Tel. (direct): +45 4446 0738

Tel. (mobile): +45 3077 0738

Thomas Bomhoff (USA)

Tel. (direct): +1 919 494 3483

Tel. (mobile): +1 919 649 2565

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.